
Enhancer assays support the accuracy of PRISM predictions. (A) Fifteen predicted MYF6 targets that PRISM implicates in pancreas development (estimated binding site FDR = 46%) were tested for enhancer activity and responsiveness to MYF6 in mPAC cells, which are derived from pancreatic ductal cells. Firefly luciferase to Renilla luciferase ratios were normalized to empty vector. Error bars show standard error of the mean over three replicates. (*) A significant (unpaired t-test, P-value < 0.05) response to MYF6 cotransfection (for 8/15 elements = 53%). (B) Predicted PRISM targets were tested across four cell lines matched in context to the PRISM prediction. Across all sets, 67% of the targets respond significantly to the transcription factor predicted by PRISM.











